Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01989325 · ClinicalTrials.gov registry record · Phase 2
A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT01989325: Completed Phase 2 study, sponsored by Pfizer.
NCT01989325 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 77 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01989325, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. Approximately 75 patients from the US will be enrolled in this study.
Interventions
- DRUG Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
- DRUG Carfilzomib, proteasome inhibitor; intravenous
- DRUG Filanesib, KSP(Eg5) inhibitor; intravenous
- DRUG Dexamethasone, steroid; oral or intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
What the finished NCT01989325 record still lists
NCT01989325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 4 interventions - of which Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous is the first listed.
NCT01989325 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01989325 about?
NCT01989325 is a clinical study titled "A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma". This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzo...
What is the current status of trial NCT01989325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2013-11. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01989325?
The interventions under investigation include: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous (DRUG), Carfilzomib, proteasome inhibitor; intravenous (DRUG), Filanesib, KSP(Eg5) inhibitor; intravenous (DRUG), Dexamethasone, steroid; oral or intravenous (DRUG).
Who is sponsoring clinical trial NCT01989325?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01989325's enrollment target sits among peer trials
77 891st of 2000 higher than 1,108 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia